The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Biogen Safe Harbor This news release contains forward-looking statements, including related to the potential clinical effects of a higher dose regimen of nusinersen; the potential benefits ...

Biogen has decided to close down its digital ... competition and spinal muscular atrophy (SMA) treatment Spinraza (nusinersen), which has seen its growth stalled by rival therapies entering ...

have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza (nusinersen). The proposed higher dose regimen includes two 50mg doses ...

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033, according to ...

Treatment with Spinraza (nusinersen) can help stabilize motor function in adults ... Spinraza is administered by injection into the spinal canal every four months. It’s sold by Biogen. Note: The SMA ...

For instance, in January 2025, the U.S. FDA has accepted Biogen’s supplemental new drug application (sNDA) for a higher, potentially more efficacious dose regimen of nusinersen (Spinraza) for patients ...